Literature DB >> 10411695

Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats.

D J Campbell1, D J Kelly, J L Wilkinson-Berka, M E Cooper, S L Skinner.   

Abstract

BACKGROUND: The transgenic (mRen-2)27 rat (TGR) is a high tissue renin, high angiotensin (Ang) II model of hypertension. When administered streptozotocin (STZ), TGRs develop a rapidly progressive diabetic nephropathy with renal failure over 12 weeks. Bradykinin (BK) and Ang II are potent vasoactive peptides that may participate in the vascular and metabolic abnormalities of diabetes.
METHODS: TGR and Sprague-Dawley (SD) rats were administered STZ (diabetic) or citrate buffer (nondiabetic) at six weeks of age. Diabetic rats received daily ultralente insulin to maintain moderate hyperglycemia ( approximately 18 mM). Rats were sacrificed four- and eight-weeks post-STZ or vehicle.
RESULTS: Diabetes did not modify the blood pressure of either SD rats or TGRs. Diabetes increased levels of BK-(1-9) and its metabolite BK-(1-7) in kidney, aorta, and heart of both SD rats and TGRs. Diabetes did not influence Ang II levels in plasma, kidney, aorta, heart, or adrenal gland of SD rats, but reduced to normal the elevated Ang II levels in plasma, kidney, aorta, and adrenal gland of TGRs.
CONCLUSIONS: STZ-induced diabetes was associated with elevated tissue levels of BK-(1-9) and "normal" circulating and tissue levels of Ang II. The increased BK-(1-9) levels were consistent with the participation of this peptide in the vascular and metabolic abnormalities of diabetes. However, the rapidly progressive nephropathy of diabetic TGRs was not associated with BK-(1-9) and Ang II levels in target organs that differed from those of diabetic SD rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411695     DOI: 10.1046/j.1523-1755.1999.00519.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

1.  Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat.

Authors:  J L Wilkinson-Berka; G Tan; K J Binger; L Sutton; K McMaster; D Deliyanti; G Perera; D J Campbell; A G Miller
Journal:  Diabetologia       Date:  2011-07-14       Impact factor: 10.122

2.  Renal tubular ACE-mediated tubular injury is the major contributor to microalbuminuria in early diabetic nephropathy.

Authors:  Masahiro Eriguchi; Mercury Lin; Michifumi Yamashita; Tuantuan V Zhao; Zakir Khan; Ellen A Bernstein; Susan B Gurley; Romer A Gonzalez-Villalobos; Kenneth E Bernstein; Jorge F Giani
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

3.  Increased tissue kallikrein levels in type 2 diabetes.

Authors:  D J Campbell; A Kladis; Y Zhang; A J Jenkins; D L Prior; M Yii; J F Kenny; M J Black; D J Kelly
Journal:  Diabetologia       Date:  2010-01-10       Impact factor: 10.122

Review 4.  Blood pressure lowering for the prevention and treatment of diabetic kidney disease.

Authors:  Merlin C Thomas; Robert C Atkins
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin.

Authors:  Atsuhiro Ichihara; Matsuhiko Hayashi; Yuki Kaneshiro; Fumiaki Suzuki; Tsutomu Nakagawa; Yuko Tada; Yukako Koura; Akira Nishiyama; Hirokazu Okada; M Nasir Uddin; A H M Nurun Nabi; Yuichi Ishida; Tadashi Inagami; Takao Saruta
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

6.  Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Ravi Nistala; Javad Habibi; Melvin R Hayden; Rebecca I Schneider; Megan S Johnson; Roger Tilmon; Nathan Rehmer; Carlos M Ferrario; James R Sowers
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-09

7.  Na+,K+-ATPase is modulated by angiotensin II in diabetic rat kidney--another reason for diabetic nephropathy?

Authors:  Andrea Fekete; Klara Rosta; Laszlo Wagner; Agnes Prokai; Peter Degrell; Eva Ruzicska; Edit Vegh; Miklos Toth; Katalin Ronai; Krisztina Rusai; Aniko Somogyi; Tivadar Tulassay; Attila J Szabo; Agota Ver
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

Review 8.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

9.  The Absence of the ACE N-Domain Decreases Renal Inflammation and Facilitates Sodium Excretion during Diabetic Kidney Disease.

Authors:  Masahiro Eriguchi; Ellen A Bernstein; Luciana C Veiras; Zakir Khan; Duo Yao Cao; Sebastien Fuchs; Alicia A McDonough; Jorge E Toblli; Romer A Gonzalez-Villalobos; Kenneth E Bernstein; Jorge F Giani
Journal:  J Am Soc Nephrol       Date:  2018-09-05       Impact factor: 10.121

Review 10.  Innate immunity in diabetic kidney disease.

Authors:  Sydney C W Tang; Wai Han Yiu
Journal:  Nat Rev Nephrol       Date:  2020-01-15       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.